Case Comprehensive Cancer Center: Adenocarcinoma trials

The registry lists 11 Adenocarcinoma studies with Case Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 2Phase 2 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination ChemotherapyTerminatedNCT02392377Phase 2Results posted
• Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II StudyTerminatedNCT02345460Phase 2Results posted
• Enzalutamide in Patients With High-risk Prostate CancerCompletedNCT01927627Phase 2Results posted
• Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic CancerCompletedNCT01666730Phase 2Results posted
• Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)TerminatedNCT01395537Phase 1/2Results posted
• Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic CancerCompletedNCT02153450Early Phase 1
• FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal AdenocarcinomaActive, not recruitingNCT02037048Phase 2
• Treatment Decision Analysis Model for Prostate Cancer: A Randomized TrialTerminatedNCT02024685Not applicable
• Assisted Exercise in Obese Endometrial Cancer PatientsCompletedNCT01870947Not applicable
• Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal CancerWithdrawnNCT01403103Early Phase 1
• Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00732745Phase 1